Steatohepatitis/Metabolic Liver Disease

You have free access to this content

Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease†‡

  1. Vincent Wai-Sun Wong1,2,
  2. Julien Vergniol3,
  3. Grace Lai-Hung Wong1,2,
  4. Juliette Foucher3,
  5. Henry Lik-Yuen Chan1,2,
  6. Brigitte Le Bail4,5,
  7. Paul Cheung-Lung Choi6,
  8. Mathurin Kowo3,
  9. Anthony Wing-Hung Chan6,
  10. Wassil Merrouche3,
  11. Joseph Jao-Yiu Sung1,2,
  12. Victor de Lédinghen3,4,§,*

Article first published online: 9 SEP 2009

DOI: 10.1002/hep.23312

Issue

Hepatology

Hepatology

Volume 51, Issue 2, pages 454–462, February 2010

Additional Information

How to Cite

Wong, V. W.-S., Vergniol, J., Wong, G. L.-H., Foucher, J., Chan, H. L.-Y., Le Bail, B., Choi, P. C.-L., Kowo, M., Chan, A. W.-H., Merrouche, W., Sung, J. J.-Y. and de Lédinghen, V. (2010), Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology, 51: 454–462. doi: 10.1002/hep.23312

Author Information

  1. 1

    Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China

  2. 2

    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China

  3. 3

    Centre d'Investigation de la Fibrose Hépatique, Centre Hospitalier Universitaire (CHU) de Bordeaux, Hôpital Haut-Lévêque, France

  4. 4

    Institut National de la Santé et de la Recherche Médicale U889, Université Victor Segalen, Bordeaux, France

  5. 5

    Service d'Anatomie Pathologique, CHU de Bordeaux, Hôpital Pellegrin, France

  6. 6

    Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong, China

  1. §

    fax: (33)-557-656-445.

*Service d'Hépato-Gastroentérologie, Hôpital Haut-Lévêque, 33604 Pessac Cedex, France

  1. †

    See Editorial on page 370.

  2. ‡

    Potential conflict of interest: Dr. Chan advises and is on the speakers' bureau of Novartis and Bristol-Myers Squibb. He also advises Pharmasset and Schering-Plough. Dr. Sung advises and is on the speakers' bureau of AstraZeneca, GlaxoSmithKline, and Roche.

Publication History

  1. Issue published online: 25 JAN 2010
  2. Article first published online: 9 SEP 2009
  3. Accepted manuscript online: 9 SEP 2009 12:00AM EST
  4. Manuscript Accepted: 2 SEP 2009
  5. Manuscript Received: 18 JUL 2009

Funded by

  • Research fund of the Department of Medicine and Therapeutics, The Chinese University of Hong Kong

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (263K)

References

  • 1
    Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008; 134: 1682–1698.
  • 2
    Wong VW, Hui AY, Tsang SW, Chan JL, Tse AM, Chan KF, et al. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4: 1154–1161.
  • 3
    Wong VW, Hui AY, Tsang SW, Chan JL, Wong GL, Chan AW, et al. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2006; 24: 1215–1222.
  • 4
    Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134–140.
  • 5
    Hui AY, Wong VW, Chan HL, Liew CT, Chan JL, Chan FK, et al. Histological progression of non-alcoholic fatty liver disease in Chinese patients. Aliment Pharmacol Ther 2005; 21: 407–413.
  • 6
    Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. HEPATOLOGY 2006; 44: 865–873.
  • 7
    Merriman RB, Ferrell LD, Patti MG, Weston SR, Pabst MS, Aouizerat BE, et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. HEPATOLOGY 2006; 44: 874–880.
  • 8
    Guha IN, Parkes J, Roderick PR, Harris S, Rosenberg WM. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut 2006; 55: 1650–1660.
  • 9
    Wong VW, Wong GL, Chim AM, Tse AM, Tsang SW, Hui AY, et al. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol 2008; 103: 1682–1688.
  • 10
    Talwalkar JA, Kurtz DM, Schoenleber SJ, West CP, Montori VM. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2007; 5: 1214–1220.
  • 11
    Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960–974.
  • 12
    Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56: 968–973.
  • 13
    Wong GL, Wong VW, Choi PC, Chan AW, Chum RH, Chan HK, et al. Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. Clin Gastroenterol Hepatol 2008; 6: 1027–1035.
  • 14
    Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. HEPATOLOGY 2003; 38: 518–526.
  • 15
    Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. HEPATOLOGY 2006; 43: 1317–1325.
  • 16
    Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ; Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1104–1112.
  • 17
    Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. HEPATOLOGY 2007; 45: 846–854.
  • 18
    Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: 1441–1447.
  • 19
    Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. HEPATOLOGY 2005; 41: 1313–1321.
  • 20
    Yoneda M, Mawatari H, Fujita K, Endo H, Iida H, Nozaki Y, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008; 40: 371–378.
  • 21
    de Ledinghen V, Douvin C, Kettaneh A, Ziol M, Roulot D, Marcellin P, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41: 175–179.
  • 22
    Gomez-Dominguez E, Mendoza J, Rubio S, Moreno-Monteagudo JA, Garcia-Buey L, Moreno-Otero R. Transient elastography: a valid alternative to biopsy in patients with chronic liver disease. Aliment Pharmacol Ther 2006; 24: 513–518.
  • 23
    Chan HL, Wong GL, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepatol 2009; 16: 36–44.
  • 24
    Nahon P, Kettaneh A, Tengher-Barna I, Ziol M, de Ledinghen V, Douvin C, et al. Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. J Hepatol 2008; 49: 1062–1068.
  • 25
    Nobili V, Vizzutti F, Arena U, Abraldes JG, Marra F, Pietrobattista A, et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. HEPATOLOGY 2008; 48: 442–448.
  • 26
    Arena U, Vizzutti F, Corti G, Ambu S, Stasi C, Bresci S, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. HEPATOLOGY 2008; 47: 380–384.
  • 27
    Sagir A, Erhardt A, Schmitt M, Haussinger D. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. HEPATOLOGY 2008; 47: 592–595.
  • 28
    Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol 2009; 24: 1002–1007.
  • 29
    Millonig G, Reimann FM, Friedrich S, Fonouni H, Mehrabi A, Buchler MW, et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. HEPATOLOGY 2008; 48: 1718–1723.
  • 30
    Wong VW, Wong GL, Tsang SW, Hui AY, Chan AW, Choi PC, et al. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. Aliment Pharmacol Ther 2009; 29: 387–396.
  • 31
    Lucidarme D, Foucher J, Le Bail B, Vergniol J, Castera L, Duburque C, et al. Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. HEPATOLOGY 2009; 49: 1083–1089.
  • 32
    Mehta SH, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver histology markers. J Hepatol 2009; 50: 36–41.
  • 33
    De Ledinghen V, Fournier C, Foucher J, Miette V, Vergniol J, Rigalleau V, et al. New Fibroscan probe for obese patients: a pilot study of feasibility and performances in patients with BMI >30 kg/m2. J Hepatol 2009; 50( Suppl 1): S359.
View Full Article (HTML) Get PDF (263K)